A Study of the Combination of Necitumumab (LY3012211) and Pembrolizumab (MK3475) in Participants With NSCLC

Clinical trial NCT02451930 · COMPLETED

Trial details

NCT number: NCT02451930
Sponsor: Eli Lilly and Company
Status: COMPLETED
Phase: Phase 1
Study type: INTERVENTIONAL

Stage IV Non-Small Cell Lung Cancer

Start date: 2015-09-04
Primary completion: 2017-01-26
Enrollment: 71

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.